| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3-Hydroxy-4-aminopyridine does not have a well-defined pharmacological target, as it is primarily an endogenous metabolite and impurity. It is a metabolite of the potassium channel blocker Fampridine. The compound may interact with various enzymes and receptors, but its specific binding targets have not been fully characterized. It is not used as a therapeutic agent.
|
|---|---|
| ln Vitro |
3-Hydroxy-4-aminopyridine does not possess significant pharmacological activity as a pure compound in typical in vitro assays, as it is primarily an endogenous metabolite. Studies may involve measuring its presence as a metabolite of Fampridine or as an impurity in pharmaceutical preparations. The compound is used as a reference standard in analytical chemistry. It is not studied for specific biological activities.
|
| ln Vivo |
In vivo activity of 3-Hydroxy-4-aminopyridine is related to its role as a metabolite of the potassium channel blocker Fampridine. It is formed in the body through the metabolism of Fampridine. However, the compound itself is not used therapeutically, and comprehensive in vivo studies evaluating its pharmacokinetic properties, efficacy, and safety are limited. Its toxicity profile is primarily related to its role as a metabolite and impurity.
|
| Enzyme Assay |
In vitro enzyme/receptor binding experiments for 3-Hydroxy-4-aminopyridine are not typical, as it is a metabolite rather than a pharmacologically active compound. Studies may involve measuring its presence as a metabolite of Fampridine or as an impurity in pharmaceutical preparations. Its chemical properties are characterized using standard analytical methods such as HPLC and mass spectrometry. The compound is also used as a reference standard in analytical chemistry.
|
| Cell Assay |
In vitro cellular experiments for 3-Hydroxy-4-aminopyridine are not typical, as it is a metabolite rather than a pharmacologically active compound. The compound may be used in studies to evaluate its cytotoxicity or its metabolism in cell lines. However, comprehensive in vitro cellular studies are limited. The compound's aminopyridine structure may interact with cellular targets, but its activity is not well characterized.
|
| Animal Protocol |
In vivo animal experiments for 3-Hydroxy-4-aminopyridine are not typical, as it is a metabolite rather than a drug candidate. Studies may involve administering Fampridine to animals and measuring the levels of 3-Hydroxy-4-aminopyridine as a metabolite. However, comprehensive in vivo studies evaluating its pharmacokinetic properties are limited.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of 3-hydroxy-4-aminopyridine include 4-amino-3-hydroxypyridine sulfate. Pharmacokinetic properties of 3-Hydroxy-4-aminopyridine are related to its role as a metabolite of Fampridine. It is formed in the body through the metabolism of Fampridine. The compound's physicochemical properties, such as molecular weight (110.11) and solubility, are typical of aminopyridines. Detailed pharmacokinetic studies are limited. |
| Toxicity/Toxicokinetics |
Toxicological data for 3-Hydroxy-4-aminopyridine are limited. As a metabolite and impurity, it may have toxicological implications, but comprehensive toxicology studies have not been extensively reported. Standard safety precautions for handling aminopyridines apply, including the use of personal protective equipment and working in a well-ventilated area. The toxicological properties of this substance have not been fully investigated.
|
| Additional Infomation |
3-Hydroxy-4-aminopyridine is an aminopyridine.
3-Hydroxy-4-aminopyridine is a research compound that has not entered clinical trials or received regulatory approval for therapeutic use. It is primarily used as a reference standard in analytical chemistry and as a metabolite of the potassium channel blocker Fampridine. The compound is an endogenous metabolite and is also known as 4-aminopyridin-3-ol. Further research is needed to explore its potential biological activities. |
| Molecular Formula |
C₅H₆N₂O
|
|---|---|
| Molecular Weight |
110.11
|
| Exact Mass |
110.048
|
| CAS # |
52334-53-9
|
| PubChem CID |
2762419
|
| Appearance |
White to light brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
447.4±30.0 °C at 760 mmHg
|
| Melting Point |
222-223ºC
|
| Flash Point |
224.4±24.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.651
|
| LogP |
0.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
76.8
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DBDKLFOUWUHPDW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H6N2O/c6-4-1-2-7-3-5(4)8/h1-3,8H,(H2,6,7)
|
| Chemical Name |
4-aminopyridin-3-ol
|
| Synonyms |
3Hydroxy4aminopyridine; 3 Hydroxy 4 aminopyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~151.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (18.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (18.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (15.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.0818 mL | 45.4091 mL | 90.8183 mL | |
| 5 mM | 1.8164 mL | 9.0818 mL | 18.1637 mL | |
| 10 mM | 0.9082 mL | 4.5409 mL | 9.0818 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
